SCHEMBL30458086

SCHEMBL30458086

CNC(C)Cc1cc2ccccc2o1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.51
AGXT P21549 1/20 0.47
TAAR1 Q96RJ0 2/20 0.46
SLC18A2 Q05940 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
HTR1B P28222 4/20 0.45
PSMB5 P28074 2/20 0.45
PSMB8 P28062 1/20 0.45
PIN1 Q13526 1/20 0.44
CYP2D6 P10635 1/20 0.42
HIF1A Q16665 1/20 0.42
FCER2 P06734 1/20 0.42
HTR1A P08908 1/20 0.41
HTR2B P41595 1/20 0.41
MKNK1 Q9BUB5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30457961 1.00 LOXL2 (0.51) LOXL2AGXTTAAR1SLC18A2SIGMAR1
SCHEMBL30458044 0.84 SIGMAR1 (0.49) LOXL2AGXTSIGMAR1MEN1NPC1
SCHEMBL30457823 0.84 SIGMAR1 (0.49) LOXL2AGXTSIGMAR1MEN1NPC1
SCHEMBL5962355 0.82 LOXL2 (0.58) LOXL2AGXTMEN1NPC1RAB9A
SCHEMBL30457900 0.81 TAS1R3 (0.50) LOXL2AGXTHTR1BPSMB5PSMB8
SCHEMBL11291792 0.79 LOXL2 (0.55) LOXL2AGXTMEN1NPC1RAB9A
SCHEMBL2022678 0.79 LOXL2 (0.59) LOXL2AGXTTAAR1SIGMAR1MEN1
SCHEMBL25274325 0.78 LOXL2 (0.46) LOXL2AGXTMEN1NPC1RAB9A
SCHEMBL19550896 0.78 LOXL2 (0.43) LOXL2AGXTSIGMAR1MEN1NPC1
SCHEMBL14075637 0.76 LOXL2 (0.69) LOXL2AGXTHTR1AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4444283-A1 SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT Tactogen Inc. (US) 2024-10-16 EP claimed
WO-2023107715-A1 SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT TACTOGEN INC (US) 2023-06-15 WO claimed
US-20250188049-A1 ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2025-06-12 US disclosed
EP-4444283-A1 SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT Tactogen Inc. (US) 2024-10-16 EP disclosed
WO-2024108179-A2 2-ETHYLAMINE SUBSTITUTED BENZOFURAN AND BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2024-05-23 WO disclosed
CN-116332340-A Biochar scrap iron coupling filler and preparation method and application thereof 云南省烟草公司玉溪市公司 2023-06-27 CN disclosed
WO-2023107715-A1 SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT TACTOGEN INC (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188049-A1 ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT BDNF, CREBBP, ELF3 LOXL2 1343/4885AGXT 90/4885TAAR1 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.